AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02774681 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Ancillary studies
Study NCT02774681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study NCT02774681 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02770924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AT LISA TRI
Description: phacoemulsification with IOL implantation
Study NCT02774681 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT02282696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire, focus group participation
Description: participants of the quantitative part of the study are asked to fill in a questionnaire, participants of the qualitative part are asked to participate in a focus group interview.
Study NCT03221985 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: questionnaires
Description: questionnaire with application on smartphone
Study NCT01242657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Module
Description: Participants were provided pedometers in order to track specific Step Goals, which were defined for male or female participants. In addition, each participant recorded other forms of physical activity in a Challenge Log.
Study NCT01242657 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Not On Tobacco (N-O-T) Program
Description: Not On Tobacco (N-O-T) Program, a proven teen smoking cessation program
Study NCT00321451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Description: 4 biweekly outpatient sessions with sleep psychologist
Study NCT01242657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Not On Tobacco (N-O-T) Program
Description: Not On Tobacco (N-O-T) Program, a proven teen smoking cessation program
Study NCT04204018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Arm
Description: * First, these providers will receive educational materials (e.g. a slide deck) meant to mimic what physicians will receive in the real-world market as they learn about the Progenity technology.~* Second, within each of their four cases, intervention-arm physicians only will receive simulated test results from the Progenity PE test at the clinically-appropriate point in each case.
Study NCT02206516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Study NCT00321451 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Pseudo-desensitization procedure
Description: 4 biweekly outpatient visits with sleep psychologist
Study NCT00321451 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: 3 outpatient visits with study physician
Study NCT00445185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Henogen HB vaccine
Description: Month 12, 24 and 36
Study NCT02011048 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic components separation
Description: Endoscopic components separation hernia repair
Study NCT00445185 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fendrix vaccine
Description: Month 12, 24 and 36
Study NCT03788733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Description: 1 time a day for 8 weeks
Study NCT00402467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939)
Description: 2.5mg bid
Study NCT00402467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban, (BAY59-7939)
Description: 5mg bid
Study NCT00402467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban, (BAY59-7939)
Description: 10 mg bid
Study NCT00402467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban, (BAY59-7939)
Description: 20mg bid
Study NCT00402467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparine
Description: 30mg bid
Study NCT03636126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR + TACS
Description: TACS- A regulated class of transcranial alternating current stimulation (tACS), called Cranial Electrotherapy Stimulation (CES) by Fisher Wallace Laboratories (FWL) is FDA-Cleared to treat depression, anxiety, and insomnia (Proof of FDA clearance and 510k provided in the appendix). FWL tACS delivers weak non-invasive electrical stimulation (1-4 milliamps at 15, 500, and 15,000 Hz) to the frontal/temporal brain regions by electrodes placed above the temples. Land's End Virtual Reality Game Meta-analyses show Virtual Reality (VR) is an effective non-pharmacological method that reduces obstacles to human performance such as pain, insomnia, anxiety, sleep deprivation, and a variety of other stress responses.
Study NCT04688749 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electrical Impedence Spectroscopy DermaSense
Description: Two sets of measurements will be performed to each subject, either at a nevus in contrast with a nearby clear patch of skin. The duration of each measurement will last for approximately 1.5 minutes and the excel file will be directly available to researcher, allowing him/her for data storage and data visualization.
Study NCT00519272 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Series of surveys to be completed at the time of diagnosis and within one month after completion of treatment, taking approximately 45 minutes each time.
Study NCT03449069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC-AFP
Description: Patients will have a mesenchymal stromal cell coated anal fistula plug placed in their Crohn's perianal fistula tract.
Study NCT00118872 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo yogurt
Description: Yogurt NOT containing the active LGG bacteria
Study NCT03418636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staying Safe (Ssafe)
Description: Staying Safe motivates and teaches young people who inject drugs (PWID) planning skills and drug use management strategies to enable long-term risk avoidance and the implementation of healthy protective behaviors. Content is presented through guided discussions and role playing exercises, and relies heavily on interactive participation by group members to foster peer-based learning and social reinforcement processes.
Study NCT03418636 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living
Description: The content of the Healthy Living intervention is based on the DHHS' Eat Healthy, Be Active Community Workshop curriculum, supplemented with basic sleep hygiene education. Science-based dietary and light physical activity guidelines are demonstrated and promoted to help participants develop and maintain a healthy lifestyle.
Study NCT03981679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological collection
Description: The biological collection will also include samples of blood samples collected before colonoscopy
Study NCT02047214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
Study NCT02047214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
Study NCT05176236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pictographic tracheostomy care handouts
Description: The handouts were developed and validated by Clinical and inter-professional experts based on the hospital's text-based tracheostomy home care instructions.
Study NCT02211248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary assistance
Description: Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
Study NCT02211248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment and follow up
Description: Assistance was effected by physician and nurse and consisted about adapting to the drug
Study NCT03788733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral
Description: 1 time a day for 8 weeks
Study NCT02806726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iDesign 1.3-PRESBY treatment
Description: Software used to calculate the LASIK treatment profile including a presbyopic correction component for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
Study NCT02806726 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iDesign 1.3 treatment
Description: Software used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
Study NCT03289104 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Steel Wires
Description: Control: Steel wires (device) are selected for sternal closure after surgery. Currently, most patients who have a sternotomy during cardiac surgery have their sternum closed with steel wires.
Study NCT00080301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone + Capecitabine
Description: Ixabepilone - Intravenous Solution, IV 40mg/m², Day 1 every 21 days, Until progression/unacceptable toxicity~Capecitabine (Active Comparator) - Tablet, Oral, 2000 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
Study NCT00080301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Tablet, Oral, 2500 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
Study NCT04389723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Qualia Mind
Description: Multi-ingredient Dietary supplement
Study NCT04389723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Multi-ingredient Placebo
Study NCT00377858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro mid mixture (MM)
Description: Patient specific adjusted dose, three times a day (TID), subcutaneous (SC) injection x 36 weeks
Study NCT00377858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Patient specific adjusted dose, every day (QD), subcutaneous (SC) injection x 36 weeks
Study NCT00991939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone USP Micronized
Description: The dose for dexamethasone is 30 mg/day for patients \< 60 kg and 40 mg/day for patients > 60 kg. The patient will be dosed on days 1-4, 15-18 and 29-32. On the remaining days during the treatment phase of the study, the patient will receive placebo capsules.
Study NCT00991939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone will be administered to study patients at a dose of 60 mg/day for patients less than 60 kg and 80 mg/day for patients > 60 kg for 21 days. The following schedule for tapering of prednisone will be used: after three weeks of treatment at either 60 mg/day (for patients \< 60 kg) or 80 mg/day (for patients ≥ 60 kg), the dose will be reduced to 40 mg/day for 1 week, then 20 mg/day for 1 week, then 10 mg/day for 1 week, then 5 mg/day for 1 week and then stopped. Placebo capsules will be added as necessary during the treatment phase of the study, to maintain blinding.
Study NCT02457156 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blumgart Anastomosis
Description: 1. Trans pancreatic suture U stich incorporating pancreatic parenchyma and jejunal serosa, left loose.~2. Pancreatic duct to jejunal mucosa sutures, inserted and tied.~3. Trans pancreatic suture U stich brought back through the jejuanl serosa anteriorly, tied.
Study NCT02457156 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cattell-Warren Anastomosis
Description: 1. Posterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied.~2. Pancreatic duct to jejunal mucosa sutures, inserted and tied.~3. Anterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied.
Study NCT02457156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Octrotide (100ug) to be administered on the evening before surgery and then 100ug three times daily on the day of surgery and post operative days 1 - 6.
Study NCT03289104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZipFix Sternal Closure System
Description: Treatment: ZipFix system (device) are selected for sternal closure after surgery. These plastic cables can also be used to close the sternum during bypass surgery.
Study NCT00528528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Oval tablets containing 375 mg of telaprevir for oral administration.
Study NCT00528528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-alfa-2a
Description: Solution containing Peg-IFN alfa2a for subcutaneous injection in a pre-filled syringe.
Study NCT00528528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-alfa-2b
Description: Powder containing Peg-IFN-alfa-2b and solvent for solution for subcutaneous injection in a pre-filled pen.
Study NCT00528528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV) tablet
Description: Tablets containing 200 mg RBV for oral administration.
Study NCT00528528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV) capsule
Description: Capsules containing 200 mg RBV for oral administration.
Study NCT01589432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-639
Description: two 50 mg oral capsules
Study NCT01589432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo capsules
Study NCT01589432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 3mg/kg infusion over 30 minutes
Study NCT01578044 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: 1. Patient education: Patients will receive information on dabigatran, including risks, benefits and potential side effects. This information will be re-enforced during the study on a monthly basis during the IVR calls and during the pharmacy service calls to patients.~2. Tele-monitoring: We will use IVR technology to send patients an automated reminder to refill their dabigatran, rivaroxaban, and apixaban prescriptions. This call will be delivered on day 20 following each dabigatran, rivaroxaban, and apixaban prescriptions.~3. Pharmacists follow-up: If dabigatran, rivaroxaban, and apixaban have not been refilled, the pharmacy staff will contact the patient to assess reasons that the patient has not refilled the medication.
Study NCT01578044 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Usual care
Study NCT02457156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Octrotide (100ug) to be administered on the evening before surgery and then 100ug three times daily on the day of surgery and post operative days 1 - 6.
Study NCT04436497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilucoplan
Description: Drug: Zilucoplan Administration: Subcutaneous injection~Dosage: 0.3mg/kg administered daily
Study NCT04436497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Drug: Matching Placebo~Administration: Subcutaneous injection~Dosage: Daily subcutaneous injection
Study NCT00194038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Patients were continued on treatment with their existing mood stabilizing medication, and upon enrollment were initiated on aripiprazole augmentation treatment. The initial starting dose of aripiprazole was 5 mg/day, with gradual upward titration as tolerated. Initiation of new additional antipsychotic medications was not permitted during the course of the study, and antipsychotic medications prescribed at study start were tapered and discontinued by week 4 of the study if possible.
Study NCT02489682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-form written Informed consent information
Study NCT00972725 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' HIV vaccine (732461)
Description: 1 dose intramuscular injection
Study NCT00972725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' HIV vaccine (732461)
Description: 1 dose intramuscular injection
Study NCT00972725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: One dose of 300 mg
Study NCT02564185 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual practice
Study NCT02564185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual practice
Study NCT02564185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education program
Study NCT05503342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: Use of the cell phone application to include information about asthma symptoms which had returned with guidance on self-management.
Study NCT05503342 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asthma control assessment
Description: Asthma control assessment questionnaire application in paper format
Study NCT05467384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 5mg/day in two divided doses
Study NCT05370053 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELF Test
Description: Patients receive ELF testing (a blood draw) and their hepatologist receives the result within a week.
Study NCT02548338 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: argon plasma coagulation
Description: On the first group we use the regular electric scalpel to perform the surgery , and on the second group we use the argon plasma coagulation scalpel to perform the procedure.
Study NCT02598440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Participants wil receive once-weekly oral alendronate (70 mg tablet)
Study NCT02598440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Participants wil receive once-monthly oral ibandronate (150 mg tablet)
Study NCT01764555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen 2 g
Study NCT02393937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference: Metronidazole Gel 1%
Description: Participants are assigned to one of three groups in parallel for the duration of the study
Study NCT02393937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test: Metronidazole Gel 1%
Description: Participants are assigned to one of three groups in parallel for the duration of the study
Study NCT02393937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Participants are assigned to one of three groups in parallel for the duration of the study
Study NCT00123123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorhexidine gluconate oral rinse (0.12%)
Description: chlorhexidine gluconate oral rinse
Study NCT00123123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT00123123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01968330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Go!®to sleep
Study NCT01076036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorPath 200
Description: CorPath™ 200 robotically-assisted percutaneous coronary intervention
Study NCT01076036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorPath 200
Description: CorPath PCI - robotic-assisted percutaneous coronary intervention
Study NCT01004289 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postconditioning
Description: Primary angioplasty and stenting followed by brief episodes of ischemia-reperfusion performed during the first minutes of reperfusion
Study NCT01004289 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary angioplasty and stenting without additional intervention
Description: Primary angioplasty and stenting without additional intervention.
Study NCT03777761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300mg oral dose
Study NCT03777761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching placebo for tucatinib
Study NCT03777761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: 400mg single oral dose
Study NCT01818102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Width 1000 HU/Level -450 HU
Description: Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 1000 HU and level -450 HU.